Active Studies

The purpose of this study is to examine whether or not providing Chantix (varenicline) will
help African American smokers quit smoking.

The purpose of this study is to test the effectiveness of a culturally-tailored
Internet-based program that helps American Indian (AI) tribal college students quit smoking.

RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using
tamoxifen citrate, goserelin acetate, leuprolide acetate, anastrozole, letrozole, or
exemestane, may fight breast cancer by lowering the amount of estrogen the body makes.
Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for
cell growth. It is not yet know whether hormone therapy is more effective when given with or
without everolimus in treating breast cancer.

PURPOSE: This randomized phase III trial studies how well giving hormone therapy together
with or without everolimus work in treating patients with breast cancer.

Based upon the current state of science, the investigators are proposing to conduct a
randomized clinical trial in which participants are randomized post-surgery to either BIS or
circumferential (tape) measurements for follow-up arm measurements. When patients in the BIS
group have an L-Dex change that is ≥10 units higher than the pre-surgical baseline measure,
and when patients in the tape measurement group have a volume change in the at-risk arm that
is between ≥ 5% and arm), both will receive four weeks of 23-32 mm compression sleeve and gauntlet therapy.

This screening and multi-sub-study randomized phase II/III trial will establish a method for
genomic screening of similar large cancer populations followed by assigning and accruing
simultaneously to a multi-sub-study "Master Protocol". The type of cancer trait (biomarker)
will determine to which sub-study, within this protocol, a participant will be assigned to
compare new targeted cancer therapy, designed to block the growth and spread of cancer, or
combinations to standard of care therapy with the ultimate goal of being able to approve new
targeted therapies in this setting. In addition, the protocol includes a "non-match"
sub-study which will include all screened patients not eligible for any of the
biomarker-driven sub-studies. This sub-study will compare a non-match therapy to standard of
care also with the goal of approval.